William N Hait

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. doi request reprint Anticancer drug development: the grand challenges
    William N Hait
    Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA
    Nat Rev Drug Discov 9:253-4. 2010
  2. ncbi request reprint Surviving metabolic stress: of mice (squirrels) and men
    William N Hait
    Authors Affiliations Janssen R and D, LLC, Raritan, New Jersey Department of Pharmacology, Penn State University College of Medicine and Penn State Hershey Cancer Institute, Milton S Hershey Medical Center, Hershey, Pennsylvania
    Cancer Discov 4:646-9. 2014
  3. ncbi request reprint Forty years of translational cancer research
    William N Hait
    Janssen, The Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ 08869, USA
    Cancer Discov 1:383-90. 2011
  4. doi request reprint Targeted cancer therapeutics
    William N Hait
    Division of Johnson and Johnson, Ortho Biotech Oncology Research and Development, Raritan, New Jersey 08869, USA
    Cancer Res 69:1263-7; discussion 1267. 2009
  5. pmc A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells
    Hua Zhu
    Department of Pharmacology and The Penn State Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, PA 17033 0850, USA
    Cancer Biol Ther 8:1722-8. 2009
  6. pmc Phosphorylation of elongation factor-2 kinase differentially regulates the enzyme's stability under stress conditions
    Kathryn J Huber-Keener
    Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine and Milton S Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA
    Biochem Biophys Res Commun 424:308-14. 2012
  7. pmc Therapeutic targeting of autophagy in disease: biology and pharmacology
    Yan Cheng
    Department of Pharmacology and Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine and Milton S Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA
    Pharmacol Rev 65:1162-97. 2013
  8. doi request reprint AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development
    Samir N Khleif
    National Cancer Institute, Raritan, New Jersey, USA
    Clin Cancer Res 16:3299-318. 2010
  9. pmc Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition
    Yan Cheng
    Department of Pharmacology and The Penn State Cancer Institute, The Pennsylvania State University College of Medicine, and Milton S Hershey Medical Center, Hershey, Pennsylvania, United States of America
    PLoS ONE 5:e9715. 2010
  10. pmc Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy
    Hao Wu
    Department of Pharmacology, Neural and Behavioral Sciences, and the Penn State Cancer Institute, Pennsylvania State University College of Medicine and Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
    Cancer Res 69:2453-60. 2009

Collaborators

Detail Information

Publications10

  1. doi request reprint Anticancer drug development: the grand challenges
    William N Hait
    Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA
    Nat Rev Drug Discov 9:253-4. 2010
    ..What are the key challenges in anticancer drug development, and how might they be addressed?..
  2. ncbi request reprint Surviving metabolic stress: of mice (squirrels) and men
    William N Hait
    Authors Affiliations Janssen R and D, LLC, Raritan, New Jersey Department of Pharmacology, Penn State University College of Medicine and Penn State Hershey Cancer Institute, Milton S Hershey Medical Center, Hershey, Pennsylvania
    Cancer Discov 4:646-9. 2014
    ..Cancer Discov; 4(6); 646-9. ©2014 AACR...
  3. ncbi request reprint Forty years of translational cancer research
    William N Hait
    Janssen, The Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ 08869, USA
    Cancer Discov 1:383-90. 2011
    ....
  4. doi request reprint Targeted cancer therapeutics
    William N Hait
    Division of Johnson and Johnson, Ortho Biotech Oncology Research and Development, Raritan, New Jersey 08869, USA
    Cancer Res 69:1263-7; discussion 1267. 2009
    ..Finally, a detailed understanding of the target's structure and function will help anticipate and identify mechanism of drug resistance and help design drugs and combinations of drugs that retain activity...
  5. pmc A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells
    Hua Zhu
    Department of Pharmacology and The Penn State Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, PA 17033 0850, USA
    Cancer Biol Ther 8:1722-8. 2009
    ..Our study suggests that the upregulation of EMMPRIN seen in many cancers can be attributed to, at least in part, the dysfunction of p53 and thus provides new evidence for the roles of p53 in tumor development and progression...
  6. pmc Phosphorylation of elongation factor-2 kinase differentially regulates the enzyme's stability under stress conditions
    Kathryn J Huber-Keener
    Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine and Milton S Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA
    Biochem Biophys Res Commun 424:308-14. 2012
    ..The complexity of eEF-2K phosphorylation highlights the intricacies of protein synthesis control during cellular stress...
  7. pmc Therapeutic targeting of autophagy in disease: biology and pharmacology
    Yan Cheng
    Department of Pharmacology and Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine and Milton S Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA
    Pharmacol Rev 65:1162-97. 2013
    ..A better understanding of the biology of autophagy and the pharmacology of autophagy modulators has the potential for facilitating the development of autophagy-based therapeutic interventions for several human diseases. ..
  8. doi request reprint AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development
    Samir N Khleif
    National Cancer Institute, Raritan, New Jersey, USA
    Clin Cancer Res 16:3299-318. 2010
    ....
  9. pmc Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition
    Yan Cheng
    Department of Pharmacology and The Penn State Cancer Institute, The Pennsylvania State University College of Medicine, and Milton S Hershey Medical Center, Hershey, Pennsylvania, United States of America
    PLoS ONE 5:e9715. 2010
    ..The purpose of the current study was to determine the role of the eEF-2 kinase-regulated autophagy in the response of breast cancer cells to inhibitors of growth factor signaling...
  10. pmc Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy
    Hao Wu
    Department of Pharmacology, Neural and Behavioral Sciences, and the Penn State Cancer Institute, Pennsylvania State University College of Medicine and Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
    Cancer Res 69:2453-60. 2009
    ....